Spero Therapeutics, Inc. Stock Analysis & AI Score
Spero Therapeutics, Inc. (SPRO) has an ST Score of 49.8 (C+), driven by its Profitability (A+) and held back by its Valuation (D). Analysts rate it Buy.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Spero Therapeutics, Inc. (SPRO) has an ST Score of 49.8 (C+), driven by its Profitability (A+) and held back by its Valuation (D). Analysts rate it Buy.
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD
All factor grades
- ProfitabilityA+
- GrowthB
- Financial StrengthC-
- MomentumD+
- ValuationD
- Piotroski6/9
Contact
SPRO stock: frequently asked questions
What is SPRO's ST Score?
Spero Therapeutics, Inc. (SPRO) has an ST Score of 49.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SPRO a buy, hold, or sell?
Analysts rate SPRO a Buy. Our ST Score grades it C+ (49.8/100). The ST Score is a data-driven signal, not a recommendation.
What are SPRO's factor grades?
Valuation D, Profitability A+, Financial Strength C-, Momentum D+, Growth B.
What is SPRO's valuation grade?
Spero Therapeutics, Inc. (SPRO) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SPRO's growth grade?
Spero Therapeutics, Inc. (SPRO) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SPRO's profitability grade?
Spero Therapeutics, Inc. (SPRO) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SPRO's financial strength grade?
Spero Therapeutics, Inc. (SPRO) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is SPRO's Piotroski score?
Spero Therapeutics, Inc. (SPRO) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.